Medtronic to Showcase Seven Debut Innovations at CIIE’s Seventh Edition, Driving High-Quality Medical Productivity through Multi-Dimensional Spillover Effects

The 7th China International Import Expo (CIIE) enters the 10-day countdown. Medtronic will showcase nearly a hundred innovative products at this year's CIIE under the theme of "Further Beauty, Extraordinary Together." This includes 7 first-time exhibits and nearly 20 star product representatives. This year marks the 75th anniversary of Medtronic's global innovation and its 35th year of deep cultivation in China. From the world to China, Medtronic has always adhered to its mission of "alleviating pain, restoring health, and extending life." Relying on the strong influence of the CIIE platform, it accelerates innovation to empower new productivity in China's local medical industry, jointly building life health and creating extraordinary changes.

Medtronic Global Senior Vice President and Greater China President Gu Yushao stated: "Medtronic has been a long-term participant, witness, and beneficiary of the China International Import Expo (CIIE). Thanks to the CIIE platform, Medtronic has accelerated the introduction and implementation of numerous globally leading innovative medical technologies and solutions, better meeting the diverse and high-quality healthcare needs of local patients. We look forward to further expanding our 'circle of friends' in China's medical ecosystem through this year’s CIIE, deepening cooperation with all partners, and contributing to the high-quality development of China's healthcare system."

"The 'Spillover Effect' Continues to Expand, Empowering the Development of New Quality Productivity in Healthcare Across Multiple Dimensions"

The "spillover effect" of the CIIE is continuously driving the layout and upgrading of Medtronic's local value chain. On October 18, Medtronic Kandi signed an investment cooperation agreement with the Changzhou National High-Tech Industrial Development Zone to jointly build a "smart manufacturing" base and "innovation" center that integrates the production and manufacturing of high-end surgical products and equipment with innovative R&D incubation. Kandi will introduce advanced products and new technologies from Medtronic's Surgical Division to strengthen the localization strategy for integrated solutions in major surgeries and create a medical technology innovation hub in the Yangtze River Delta.

As a microcosm, Medtronic has made several local investments that have withstood the test of time and yielded results. Since its upgrade in 2022, the Medtronic Kanghui Changzhou Science and Technology Park has served the dual functions of being a global production base for Medtronic's orthopedics and neurosurgery fields, as well as the global headquarters for Kanghui Medical. Multiple localized orthopedic and neurosurgery products have successfully emerged from this science park, including Medtronic’s first locally produced spinal surgery robot, the Mazor XC, China’s first domestically produced spinal surgery navigation system, the Qinhang EngineNav, and the intraoperative neuromonitoring system, NIM-Eclipse. Meanwhile, the Medtronic Lingang Medical Technology Industry Base, inaugurated in 2023, completed the rollout of its first product in March this year.

Committed to innovation, Medtronic has been actively enhancing its local R&D capabilities in China. Ji Ling, head of Medtronic's China R&D Center, stated that since its establishment in 2012, the center has developed a total of 65 products, over 50 of which have successfully entered the market, with 23 achieving global sales. Among these, the localization project for the RespArray patient monitor, initiated in 2022, has already completed product development and testing within just one year and has been submitted to the National Medical Products Administration (NMPA) for approval, with expectations to launch by the end of this year. In terms of blood glucose management, the leading Smart Blood Glucose Management Workstation co-developed by Medtronic’s China R&D Center features advanced information technology and real-time high/low blood glucose alert functions. When used in conjunction with the MiniMed™ 720G insulin pump, it enables comprehensive intelligent blood glucose management across medical facilities in China.

Medtronic and CIIE Have Walked Hand in Hand Until Now: Nearly 20 "Star Products" of CIIE Have Transformed from "Exhibits to Goods", Serving Local Doctors and Patients Better. For Example, Medtronic StealthStation FlexENT ENT Surgical Navigation System Was Approved for Marketing in August This Year, Enhancing Intraoperative Visualization, Lifting the Veil on the "Surgical Forbidden Zone" of the Skull Base Area, and Assisting in Optimizing Endoscopic Sinus Surgery; Symplicity Spyral RDN System for Treating Refractory Hypertension with Interventional Surgery Was Approved for Marketing in April This Year; The First Localization Product of Foreign Brands in China's Neurointervention Field - MeiAnXin Coil (Mechanical Detachable Coil) Was Launched in 2023; The Debut of PillCam Small Intestine Capsule Endoscope Allows People Over 2 Years Old to Undergo Non-invasive Small Intestine Examination.

Accelerate "Medical Innovation" and Strengthen the Core Development of New Quality Medical Productivity

At the pre-exhibition warm-up meeting of Medtronic, seven products making their debut were previewed in advance. The globally first showcased CoreValve Evolut FX+ Transcatheter Aortic Valve Replacement System, compared to the previous generation of TAVR products from Medtronic, features a fully upgraded design with a “large” window on the valve frame. This design concept provides more space for future coronary intervention catheter operations.

Four Asia-Pacific premier exhibits focus on neuromodulation, pain management, and cardiac and vascular fields, meeting clinical treatment needs through innovative technologies. These include: Percept RC (commonly known as a brain pacemaker), the world’s first rechargeable deep brain stimulation device with sensing capabilities for treating brain disorders such as Parkinson's disease, essential tremor, epilepsy, and dystonia; Medtronic’s next-generation SynchroMed III implantable drug infusion pump, which delivers medication directly into the intrathecal space via a catheter to treat cancer pain, other chronic pain, and spasticity; the VitalFlow ECMO system, designed to support life in acute and critically ill patients, featuring high integration, portability, and ease of operation, fulfilling multi-scenario needs including bedside ECMO and transport; and the Penditure Left Atrial Appendage Closure System, specifically designed for surgical treatment of left atrial appendage management and prevention of cardioembolic stroke, reducing the risk of stroke in patients with atrial fibrillation due to its flexible design and precise closure capabilities.

In addition, Medtronic will also bring two China-first products focusing on the cardiac and vascular fields. The Nitron CryoConsole cryoablation system for surgical treatment of atrial fibrillation, and the Tri-Ad 2.0 Adams Tricuspid Annuloplasty Band for valvular surgery.